Feb. 18 at 1:08 AM
$TCBP According to the annual report released in May 2025, over
$40 million of shareholder capital was invested solely into IP research. Yet, in November 2025, this core asset was sold to CytoMed Therapeutics at a staggering "fire-sale" price.
CytoMed, a micro-cap company with a market cap of only about
$10 million, stated that the acquisition price was so "immaterial" to their operations that they chose to keep it undisclosed. If an acquisition is "immaterial" to a
$10M company, at what absurdly low price did TCBP throw away an IP that cost shareholders
$40M to develop?
The deception goes deeper:
June 2025: TCBP had already hired a bankruptcy firm to prepare for liquidation.
August 2025: At the General Meeting, they pushed through value-destroying 'Deferred Shares'.
The Lie: They told us these shares were to "flexibly raise capital to remain a going concern."that's totally BS.
